These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8360131)

  • 21. A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica.
    Pérez V; Saénz D; Madriz J; Harhay M; Feoli J; Castro M; Odio C
    Int J Infect Dis; 2011 Aug; 15(8):e569-75. PubMed ID: 21733727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections.
    Beaucaire G; Leroy O; Beuscart C; Karp P; Chidiac C; Caillaux M
    J Antimicrob Chemother; 1991 May; 27 Suppl C():91-103. PubMed ID: 1856149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients.
    Marik PE; Lipman J; Kobilski S; Scribante J
    J Antimicrob Chemother; 1991 Nov; 28(5):753-64. PubMed ID: 1778878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once versus twice daily amikacin in neonates: prospective study on toxicity.
    Kotze A; Bartel PR; Sommers DK
    J Paediatr Child Health; 1999 Jun; 35(3):283-6. PubMed ID: 10404451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer.
    Ariffin H; Arasu A; Mahfuzah M; Ariffin WA; Chan LL; Lin HP
    J Paediatr Child Health; 2001 Feb; 37(1):38-43. PubMed ID: 11168867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of the efficacy of isepamicin in the adult core clinical trial programme.
    Carbon C
    J Chemother; 1995 Jun; 7 Suppl 2():79-85. PubMed ID: 8622115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration.
    Akers KS; Cota JM; Frei CR; Chung KK; Mende K; Murray CK
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4639-42. PubMed ID: 21825289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity.
    Langhendries JP; Battisti O; Bertrand JM; François A; Darimont J; Ibrahim S; Tulkens PM; Bernard A; Buchet JP; Scalais E
    Dev Pharmacol Ther; 1993; 20(3-4):220-30. PubMed ID: 7828457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amikacin once daily plus metronidazole versus amikacin twice daily plus metronidazole in colorectal surgery.
    Mendes da Costa P; Kaufman L
    Hepatogastroenterology; 1992 Aug; 39(4):350-4. PubMed ID: 1427582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Ann Intern Med; 1993 Oct; 119(7 Pt 1):584-93. PubMed ID: 8363169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of two amikacin dosing regimens in paediatric surgical patients.
    Forsyth NB; Botha JH; Hadley GP
    Ann Trop Paediatr; 1997 Sep; 17(3):253-61. PubMed ID: 9425382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.
    Georges B; Conil JM; Cougot P; Decun JF; Archambaud M; Seguin T; Chabanon G; Virenque C; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):360-9. PubMed ID: 16119511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individualizing amikacin regimens: accurate method to achieve therapeutic concentrations.
    Zaske DE; Cipolle RJ; Rotschafer JC; Kohls PR; Strate RG
    Ther Drug Monit; 1991 Nov; 13(6):502-6. PubMed ID: 1771647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review.
    Jenkins A; Thomson AH; Brown NM; Semple Y; Sluman C; MacGowan A; Lovering AM; Wiffen PJ;
    J Antimicrob Chemother; 2016 Oct; 71(10):2754-9. PubMed ID: 27494904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients.
    Krivoy N; Postovsky S; Elhasid R; Ben Arush MW
    Infection; 1998; 26(6):396-8. PubMed ID: 9861567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory disease.
    Ibrahim S; Derde MP; Kaufman L; Clerckx-Braun F; Jacqmin P; Brulein V; Donnez J; Tulkens PM
    Ren Fail; 1990; 12(3):199-203. PubMed ID: 2287773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
    Behre G; Link H; Maschmeyer G; Meyer P; Paaz U; Wilhelm M; Hiddemann W
    Ann Hematol; 1998 Feb; 76(2):73-80. PubMed ID: 9540761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients.
    Finley RS; Fortner CL; deJongh CA; Wade JC; Newman KA; Caplan E; Britten J; Wiernik PH; Schimpff SC
    Antimicrob Agents Chemother; 1982 Aug; 22(2):193-7. PubMed ID: 6765414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.